Conventional and non-restrictive variant of linear amplification-mediated PCR [LAM-PCR and (nr)LAM-PCR] are GeneWerk’s most sensitive assays for genome-wide integration site analysis. Developed prior to S-EPTS/LM-PCR, they have been successfully used for comprehensive and unbiased integration site retrieval in preclinical and clinical samples.
LAM-PCR has been the gold standard for ISA for over 20 years and is well known for its high sensitive detection of severe adverse events in gene therapy clinical studies. nrLAM-PCR is its non-restrictive and unbiased variation as it eliminates the need for restriction digestion.
ISA techniques that require restriction digestion rely on restriction motifs in the host genome. However, restriction motif-based detection allows the identification of only a fraction of all integration sites. nrLAM-PCR is independent of restriction motifs and amplification inefficiencies allowing unbiased detection of vector integration sites.
(nr)LAM-PCR continues to be our method of choice for the detection of rare integration sites, thanks to its high sensitivity.
However, (nr)LAM-PCR is more time-consuming than S-EPTS/LM-PCR. Therefore, it is currently recommended only in cases where extremely high sensitivity is warranted.Get in touch
Read our latest press releases and announcements below.
GeneWerk will expand capabilities to meet rapidly growing demand for cell and gene therapy...